Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
- PMID: 35597254
- DOI: 10.1016/S2213-8587(22)00134-6
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence
Conflict of interest statement
OC reports personal fees for giving lectures at congress and travel to congress from Novartis, Recordati, HRA Pharma, and Pfizer; and fees for being co-investigator in clinical research studies funded by Novartis, Recordati, and HRA Pharma. All other authors declare no competing interests.
Comment in
-
Osilodrostat for the treatment of Cushing's disease: efficacy, stability, and persistence - Authors' reply.Lancet Diabetes Endocrinol. 2022 Jun;10(6):385-387. doi: 10.1016/S2213-8587(22)00135-8. Lancet Diabetes Endocrinol. 2022. PMID: 35597255 No abstract available.
Comment on
-
Consensus on diagnosis and management of Cushing's disease: a guideline update.Lancet Diabetes Endocrinol. 2021 Dec;9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20. Lancet Diabetes Endocrinol. 2021. PMID: 34687601 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
